Meeting report from the Third Global Workshop on Melanoma.
Agarwala
Sanjiv S
SS
Department Oncology and Hematology, St. Luke's Cancer Center, Bethlehem, PA, USA. AgarwaS@slhn.org
di Pietro
Alessandra
A
Flaherty
Keith T
KT
Garbe
Claus
C
Grob
Jean-Jacques
JJ
Kashani-Sabet
Mohammed
M
Kirkwood
John M
JM
Leachman
Sancy
S
Messina
Jane
J
O'Day
Steven
S
Ribas
Antoni
A
Sondak
Vernon
V
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D015703:Antigens, CD; D000970:Antineoplastic Agents / Q000627:therapeutic use; D060908:CTLA-4 Antigen; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D005858:Germany; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D008545:Melanoma / Q000473:pathology / Q000628:therapy; D048493:Proto-Oncogene Proteins B-raf; D019009:Proto-Oncogene Proteins c-kit; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy
D020533:Angiogenesis Inhibitors; D015703:Antigens, CD; D000970:Antineoplastic Agents; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D007155:Immunologic Factors; D016898:Interferon-alpha; D019009:Proto-Oncogene Proteins c-kit; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf